Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer

Similar Items

• Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
  od: Foy, Susan P, i dr.
  Izdano: (2013)
• Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
  od: Foy, Susan P., i dr.
  Izdano: (2016)
• Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
  od: Foy, Susan P., i dr.
  Izdano: (2016)
• Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
  od: Mandl, Stefanie J, i dr.
  Izdano: (2014)
• Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
  od: Duan, Xiaopin, i dr.
  Izdano: (2019)